Watch for Elevated BPs From Injectable CGRP Antagonists

April 2021

You may see patients presenting to your ED with elevated BPs from taking an injectable CGRP antagonist used for migraine prophylaxis.

Most data suggest that erenumab (Aimovig) or other CGRP antagonists have minimal CV impact. But it's mostly short-term data in young patients without CV risks.

Now an FDA review suggests new-onset or worsening hypertension with erenumab...prompting labeling updates.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals